company background image
VRTX logo

Vertex Pharmaceuticals Informe acción NasdaqGS:VRTX

Último precio

US$493.64

Capitalización de mercado

US$128.7b

7D

3.9%

1Y

31.0%

Actualizada

06 Nov, 2024

Datos

Finanzas de la empresa +

Vertex Pharmaceuticals Incorporated

Informe acción NasdaqGS:VRTX

Capitalización de mercado: US$128.7b

Resumen de acción VRTX

Vertex Pharmaceuticals Incorporated, empresa de biotecnología, se dedica a desarrollar y comercializar terapias para el tratamiento de la fibrosis quística (FQ).

Análisis fundamental de VRTX
Puntuación del snowflake
Valoración3/6
Crecimiento futuro5/6
Rendimiento pasado0/6
Salud financiera6/6
Dividendos0/6

Recompensas

Análisis de riesgos

No se han detectado riesgos en VRTX a partir de nuestros controles de riesgos.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

Competidores de Vertex Pharmaceuticals Incorporated

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Vertex Pharmaceuticals
Precios históricos de las acciones
Precio actual de la acciónUS$493.64
Máximo en las últimas 52 semanasUS$510.64
Mínimo de 52 semanasUS$341.90
Beta0.40
1Cambio en 1 mes10.04%
Variación en 3 meses5.94%
Cambio de 1 año30.95%
3Variación en 3 años162.70%
Variación en 5 años138.36%
Variación desde la OPV10,869.78%

Noticias y actualizaciones recientes

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Nov 05

Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride

Oct 18

Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)

Oct 10

Recent updates

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Nov 05

Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride

Oct 18

Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)

Oct 10

Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug

Sep 15

Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced

Sep 05

Vertex Stock: Came For CF Drugs, Staying For Gene Therapy

Aug 02

Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Jul 11
Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Jul 09

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jun 20
If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales

Jun 17

Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time

Jun 04

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

May 09
Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 08
Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Apr 11

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Apr 05
Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15
Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22
We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07
Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25
Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

Nov 13
An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 29% Undervalued

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Oct 02
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

Jul 31
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 21% Below Their Intrinsic Value Estimate

We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Jul 03
We Ran A Stock Scan For Earnings Growth And Vertex Pharmaceuticals (NASDAQ:VRTX) Passed With Ease

Rentabilidad de los accionistas

VRTXUS BiotechsMercado US
7D3.9%0.6%-0.8%
1Y31.0%21.4%31.5%

Rentabilidad vs. Industria: VRTX superó a la industria US Biotechs, que obtuvo un rendimiento del 21.4% el año pasado.

Rentabilidad vs. Mercado: VRTX igualó el mercado US, que obtuvo un rendimiento del 31.5% el año pasado.

Volatilidad de los precios

Is VRTX's price volatile compared to industry and market?
VRTX volatility
VRTX Average Weekly Movement3.3%
Biotechs Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.8%

Precio estable de las acciones: VRTX no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de VRTX (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

FundadaEmpleadosCEOPágina web
19895,400Reshma Kewalramaniwww.vrtx.com

Vertex Pharmaceuticals Incorporated, empresa biotecnológica, se dedica a desarrollar y comercializar terapias para el tratamiento de la fibrosis quística (FQ). Comercializa TRIKAFTA/KAFTRIO para personas con FQ con al menos una mutación F508del a partir de los 2 años; SYMDEKO/SYMKEVI para personas con FQ a partir de los 6 años; ORKAMBI para pacientes con FQ a partir de 1 año; y KALYDECO para el tratamiento de pacientes con FQ a partir de 1 año con ivacaftor. La cartera de productos de la empresa incluye VX-522, un tratamiento con ARNm CFTR diseñado para tratar la causa subyacente de la fibrosis quística, que se encuentra en la fase 1 de ensayos clínicos; VX-548, un medicamento no opiáceo para el tratamiento del dolor agudo y neuropático, que se encuentra en la fase 3 de ensayos clínicos; Exa-cel, para el tratamiento de la anemia falciforme y la beta talasemia dependiente de transfusiones, que se encuentra en la fase 2/3 de ensayos clínicos.

Resumen de fundamentos de Vertex Pharmaceuticals Incorporated

¿Cómo se comparan los beneficios e ingresos de Vertex Pharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de VRTX
Capitalización bursátilUS$128.73b
Beneficios(TTM)-US$479.80m
Ingresos (TTM)US$10.63b

12.0x

Ratio precio-ventas (PS)

-265.0x

Ratio precio-beneficio (PE)

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de VRTX
IngresosUS$10.63b
Coste de los ingresosUS$4.77b
Beneficio brutoUS$5.86b
Otros gastosUS$6.34b
Beneficios-US$479.80m

Últimos beneficios comunicados

Sep 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)-1.86
Margen bruto55.13%
Margen de beneficio neto-4.52%
Ratio deuda/patrimonio0%

¿Cómo se ha desempeñado VRTX a largo plazo?

Ver rendimiento histórico y comparativa